Since data from animal breast tumors and preliminary evidence from human breast tumors indicates an excellent correlation between the presence of abundant tumor EBP and endocrine-induced breast cancer regressions, precise quantitation of EBP in all human primary tumors may prove to be an excellent prognosticator of endocrine therapy in metastatic breast cancer.
INTRODUCTION
Approximately one-third of patients with metastatic breast cancer will respond to ovariectomy, adrenalectomy, or hypophysectomy with objective evidence of tumor regression (1) (2) (3) . Experiments in this laboratory with rat mammary tumors (4) (5) (6) and preliminary data in human patients (7) indicate that tumors which contain appreciable cytoplasmic estradiol-binding protein (EBP' regress after endocrine ablation therapy whereas tumors Received for publication 13 June 1972 and in revised form 29 August 1972. 1 Abbreviations used in this paper: DCC, dextran-coated charcoal; EBP, estradiol-binding protein; E2, estradiol; Kd, dissociation constant. without EBP fail to respond. Many investigators have recently attempted to directly or indirectly detect the presence of EBP in human breast tumor specimens (7) (8) (9) (10) (11) (12) (13) . Except for two series (9, 13) none of these attempts have resulted in an actual quantitation of the number of specific estradiol-binding sites per unit of tissue.
In order to eventually correlate the absolute level of EBP in tumor specimens with the biological behavior of the tumors as well as the response to endocrine therapy, specific quantitative assays for EBP have been used in human breast cancer tissue. Earlier data derived from animal breast tumors using less sensitive methodology led to the suggestion that EBP was present or absent in an all or none fashion (4) . I now report that in both primary and metastatic human breast tumors, EBP is present in a broad concentration range from zero to very high levels expressed as estradiol-binding sites per milligram of cytoplasmic protein.
METHODS
Specimens were obtained from Wilford Hall Air Force Hospital, San Antonio, Tex. (Dr. W. Kemmerer), Memorial Hospital, New York (Dr. A. Fracchia), and the Ochsner Foundation, New Orleans, La. (Dr. A. Segaloff). Tissues were excised and placed directly into liquid nitrogen. They were then put into plastic vials and kept in freezers (-20'C to -76°C). For shipping they were put in an insulated box filled with dry ice and sent air mail-special delivery to San Antonio where they were kept in a Revco freezer (Revco, Inc., West Columbia, S. C.) (-76°C) until assay. This procedure was successful in maintaining frozen tissue unless unusual shipping delays occurred. Tissues were thawed at 4°C, then homogenized in a motor-driven glass homogenizer in 0.01 M Tris-HCl, 0.0015 M EDTA pH 7.4, 2 ml buffer per g tissue. The homogenate was then centrifuged at 160,000 g for 45 min to obtain the supernatant cytosol fraction. Protein was quantitated by the method of Lowry, Rosebrough, Farr, and Randall (14) .
Sucrose gradients. All sucrose gradients were prepared in 0.01 M Tris-HCl, 0.0015 M EDTA pH 7.4. Gradients were prepared by layering 0.5 ml 20% sucrose, 1. 
RESULTS
Of all the available methods for demonstrating EBP, sucrose gradient centrifugation is the most specific. The presence of an 8-10S peak of estradiol radioactivity unequivocally indicates the presence of EBP in a tumor cytosol. In Fig. 1 a representative human breast cancer cytosol-[3H]E2 sucrose centrifugation is displayed. The specific 8-10S peak can be seen near the bottom of the gradient and the 4-5S peak near the top. Whereas a 8-1OS peak always represents specific EBP, a 4-5S peak could represent nonspecific [3H]E2 binding, so a preincubation of an identical cytosol with a 100-fold excess of unlabeled estradiol is always included. Fig. 1 shows that the unlabeled estradiol has predictably eliminated all of the 8-1OS peak of [3H]E2, but in addition has eliminated the majority of the 4-5S peak. Therefore, in this particular cytosol, the majority of the 4-5S peak represents specific [3H]E2 binding. Fig. 2 reveals a tumor cytosol which lacks an 8-1OS peak but has an appreciable 4-5S peak. In this, instance the 4-5S peak is unaffected by nonradioactive estradiol preincubation. Hence, all of the estradiol binding observed in this tumor cytosol is nonspecific and emphasizes the need for proof of specificity in measuring EBP.
By adding increasing quantities of ['H]E2 to a constant amount of cytosol, the 8-1OS and specific 4-5S binding sites could be saturated to yield the total number of EBP sites per milligram of cytoplasm protein. However, quantitative analysis by this method would be an enormous task and would not be practical for routine use. I recommend that the sucrose gradient be run on every tumor sample for two reasons: (a) The qualitative proof of the presence of EBP (8-10S peak). (b) Evaluation of the specificity of 4-5S binding which could be important and will be discussed later.
In order to quantitate EBP the DCC method originally described by Korenmann is used (9 Fig. 4 . The data in Fig. 3 In Table II 4 Scatchard analysis of the data in Fig. 3 .
an EBP concentration of at least 9 fmol/mg cytosol protein is necessary to detect the 8-1OS peak by sucrose gradient centrifugation. DISCUSSION This report emphasizes the following two points: (a) The concentration of EBP in both primary and metastatic human mammary carcinoma varies over a wide range. Thus, an assay for EBP must be quantitative. (b) Nonspecific binding of ['H]E2 by tumor cytosol may be considerable so it is essential to have independent checks and controls to insure the specificity of the observed binding. In a report to be published elsewhere, other possible methods of measuring human EBP were examined and Sephadex gel filtration and protamine sulfate precipitation were found to be unsatisfactory. The popular in vitro tissue slice uptake method is not quantitative and requires additional controls to insure specificity. The DCC method gives accurate quantitative data and the sucrose gradient centrifugation with and without nonradioactive estradiol preincubation gives ideal specificity proof. It could be argued that the sucrose gradient method is cumbersome and expensive and that the Kd derived from the DCC assay is sufficient proof of the specificity of the interaction. This may well turn out to be true but at present the gradient centrifugation is still necessary to evaluate 4-5S binding. Steggles and King reported that a 4-5S EBP distinct from the usual 8-1OS or salt-derived 4-5S form was present in uteri of mature rats (18) . Furthermore, this 4-5S form disappeared after ovariectomy or hypophysectomy and thus could be very important in breast tumor response to endocrine ablation. We do not find this 4-5S form in the uteri of mature rats (19) but do find considerable specific 4-5S cytoplasmic binding in human breast tumors, so that until this issue is resolved it is necessary to assay 4-5S binding separately by sucrose gradient centrifugation.
Although it is not known what factors account for the wide range of EBP concentration, there are several possibilities. First, since tumors contain various cell types, the EBP concentration might be expected to vary inversely with the proportion of nonepithelial connective cells present. This is supported by the observation that although normal breast epithelial cells contain EBP, the abundance of nonepithelial cells in a random sample of normal breast prevents detection of specific EBP (9, 12, 13). However, this has been investigated in breast cancer specimens and no correlation exists between the histology of a tumor and its ability to bind estradiol (8, 10, 13) . Second, if we consider only the epithelial cells, the concentration of EBP may vary from cell to cell within a tumor since the measured EBP concentration is an integrated value for the whole tumor. This possibility could be tested by quantitative autoradiography. Finally, endogenous tumor estradiol must be considered since all available methods only measure EBP unoccupied by estradiol. Limited data on this point (9) indicates that endogenous estradiol can be measured in certain breast tumors which would produce variations in measurable EBP but since endogenous estradiol is present in exceedingly low levels only tumors with very low EBP would be significantly influenced. In summary, specific quantitative assays for EBP in human breast cancer are now available. Data from such assays correlated with future clinical responses should lead to a better understanding of endocrine-induced breast cancer regression as well as a more rational approach to therapy.
